Cargando…

Association between antenatal corticosteroids use and perinatal mortality among preterm singletons and twins in Mwanza, Tanzania: an observational study

OBJECTIVES: To examine the association between antenatal corticosteroids (ACS) use and perinatal mortality in singletons and twins delivered before 35 weeks of gestation. DESIGN: Secondary analysis of data from an observational prospective chart review study that investigated if exposure to ACS was...

Descripción completa

Detalles Bibliográficos
Autores principales: Mwita, Stanley, Kamala, Benjamin Anathory, Konje, Eveline, Ambrose, Emmanuela Eusebio, Izina, Angelina, Chibwe, Elieza, Kongola, Gilbert, Dewey, Deborah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8991063/
https://www.ncbi.nlm.nih.gov/pubmed/35393329
http://dx.doi.org/10.1136/bmjopen-2021-059030
Descripción
Sumario:OBJECTIVES: To examine the association between antenatal corticosteroids (ACS) use and perinatal mortality in singletons and twins delivered before 35 weeks of gestation. DESIGN: Secondary analysis of data from an observational prospective chart review study that investigated if exposure to ACS was associated with lower rates of perinatal mortality in preterm infants. SETTING: This study was conducted in four hospitals located in Mwanza region, Tanzania. PARTICIPANTS: The study population included all preterm singletons and twins delivered at these hospitals between 24 weeks 0 days and 34 weeks 6 days of gestation from July 2019 to February 2020. OUTCOME MEASURES: The primary outcome was perinatal mortality; the secondary outcome was respiratory distress syndrome (RDS). RESULTS: The study included 844 singletons and 210 twin infants. Three hundred and fourteen singletons (37.2%) and 52 twins (24.8%) were exposed to at least one dose of ACS. Adjusted multivariate analyses revealed that among singletons’ exposure to ACS was significantly associated with a lower likelihood of perinatal mortality, adjusted relative risk (aRR) 0.30 (95% CI 0.22 to 0.40) and RDS, aRR 0.92 (95% CI 0.87 to 0.97). In twin infants, exposure to ACS was associated with a reduced risk of RDS only, aRR 0.87 (95% CI 0.78 to 0.98). CONCLUSION: The use of ACS between 24 weeks 0 days and 34 weeks 6 days of gestation in both singletons and twins in low-resource settings is associated with positive infant outcomes. No adverse effects were noted. Further research that examines the benefits of ACS for twin infants is needed.